Clinical Trial Update: Phase 2 Study in Patients With MiT Tumors [Phase 2]

View source ↗

Summary

Phase 2 study of tivantinib in MiT family tumors including renal cell carcinoma, alveolar soft part sarcoma, and clear cell sarcoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alveolar Soft Part Sarcoma
• Clear Cell Sarcoma
• Renal Cell Carcinoma

Drugs mentioned

• tivantinib (tivantinib)

Snippet

Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | Conditions: Renal Cell Carcinoma (RCC), Alveolar Soft Part Sarcoma (ASPS) | Phase 2 | Status: COMPLETED